Zacks Research Has Bullish Outlook for PCRX FY2024 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research increased their FY2024 earnings per share estimates for Pacira BioSciences in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.60 per share for the year, up from their previous estimate of $2.36. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2025 earnings at $0.58 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.61 EPS and FY2026 earnings at $2.64 EPS.

A number of other research analysts have also recently commented on the company. Barclays decreased their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Royal Bank of Canada boosted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Jefferies Financial Group lifted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $19.86 on Monday. The business has a fifty day moving average price of $17.27 and a two-hundred day moving average price of $19.04. The stock has a market capitalization of $916.94 million, a PE ratio of -9.78 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $35.95.

Institutional Investors Weigh In On Pacira BioSciences

Hedge funds have recently modified their holdings of the company. Innealta Capital LLC bought a new position in Pacira BioSciences in the second quarter valued at about $50,000. nVerses Capital LLC increased its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after buying an additional 1,600 shares during the period. Quest Partners LLC acquired a new position in shares of Pacira BioSciences in the second quarter valued at approximately $113,000. Canada Pension Plan Investment Board bought a new position in Pacira BioSciences in the 2nd quarter valued at approximately $140,000. Finally, Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences during the 3rd quarter worth approximately $98,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.